Functional Characterization of Tau Mutation and Post-translational Modifications

Tau 突变和翻译后修饰的功能表征

基本信息

项目摘要

PROJECT SUMMARY/ ABSTRACT Protein aggregation is a hallmark of neurodegenerative diseases, including Alzheimer's Disease, and these diseases lack effective therapeutics. We currently lack an understanding of the molecular and cellular mechanisms controlling protein aggregation in the human brain, which would enable new therapeutic strategies. The protein tau aggregates in the brain in a number of neurodegenerative diseases called tauopathies, including Alzheimer's Disease. In early stages of disease, tau aggregates only in specific neurons despite being expressed in every neuron in the brain, implying that specific factors in the cellular environment predispose tau to aggregation. Similarly, tau mutations are associated with the onset of only specific tauopathies. Together, these disease features imply that tau is exquisitely sensitive to both its sequence properties and its cellular environment. Post-translational modifications (PTM) are a mechanism by which the cellular environment can act on a protein similarly to mutation. Tau is heavily post-translationally modified and changes to tau PTMs are correlated with progression of disease. Indeed, tau phosphorylation and proteolysis have been proposed to be central events in the onset and progression of tauopathies. Similarly, mutations are correlated with early disease onset and are known to hasten in vitro tau aggregation. Mutations can also cause changes in PTMs by changing tau interaction partners. The function and causality of these changes to tau sequence, however, is unknown. I hypothesize that PTMs and mutations license tau to access specific conformations to form aggregates. The goal of this proposal is to comprehensively identify (1) the biological basis of tau PTM changes and (2) how tau mutation and PTMs cause aggregation. I have shown that mitochondrial electron transport chain dysfunction causes a remodeling of tau PTMs, including the accumulation of a tau proteolytic fragment. In Aim 1, I will acquire new training in mass spectrometry (MS)-based proteomics to determine the tau PTM changes that occur due to ETC dysfunction and how those control tau aggregation. In Aim 2, I will use deep mutational scanning (DMS) to comprehensively probe tau's sequence-structure relationship. As part of Aim 2, I will use cross-link MS to directly compare in vitro and in vivo tau states to will reveal the structural mechanisms for the identified PTM and sequence changes. I am ideally positioned to complete the proposed research, as this proposal complements my training in protein biophysics and functional genomics in iPSC-derived neurons with novel MS-based techniques. Completion of this proposal will identify which PTMs and mutations control tau aggregation, as well as the development of new technologies to probe tau structure in vitro and in vivo. Completion of this proposal will provide me with essential skills and training to be a successful independent investigator.
项目总结/摘要 蛋白质聚集是神经退行性疾病的标志,包括阿尔茨海默病,并且 这些疾病缺乏有效的治疗方法。我们目前缺乏对分子和 控制人脑中蛋白质聚集的细胞机制,这将使新的 治疗策略 tau蛋白在许多称为tau蛋白病的神经退行性疾病中聚集在大脑中, 包括老年痴呆症在疾病的早期阶段,tau蛋白仅聚集在特定的神经元中, 在大脑中的每一个神经元中都有表达,这意味着细胞环境中的特定因素 使tau易于聚集。类似地,tau突变仅与特定的 tau蛋白病总之,这些疾病特征意味着tau蛋白对它的两个序列非常敏感, 特性及其细胞环境。 翻译后修饰(PTM)是细胞环境可以作用于细胞的一种机制。 蛋白质类似于突变。Tau在翻译后被严重修饰,并且Tau翻译后修饰的变化是相关的 伴随着疾病的发展事实上,tau蛋白磷酸化和蛋白水解被认为是核心 tau蛋白病的发作和进展中的事件。类似地,突变与早期疾病发作相关 并且已知加速体外tau聚集。突变也可以通过改变tau蛋白来引起PTM的变化 互动伙伴。然而,tau序列的这些变化的功能和因果关系尚不清楚。我 假设PTM和突变允许tau进入特定构象以形成聚集体。 本提案的目标是全面鉴定(1)tau PTM的生物学基础 变化和(2)tau突变和PTM如何引起聚集。我已经证明了线粒体电子 转运链功能障碍引起tau蛋白修饰修饰的重塑,包括tau蛋白水解酶的积累, 碎片在目标1中,我将获得基于质谱(MS)的蛋白质组学的新培训,以确定tau蛋白 由于ETC功能障碍而发生的PTM变化以及这些变化如何控制tau聚集。在目标2中,我将使用深度 突变扫描(DMS)来全面探测tau的序列-结构关系。作为目标2的一部分,我 将使用交联MS直接比较体外和体内tau状态,以揭示结构机制 识别的PTM和序列变化。我非常适合完成拟议的研究,因为 这个建议补充了我在蛋白质生物物理学和iPSC衍生神经元的功能基因组学方面的培训 新的MS技术。完成该提案将确定哪些PTM和突变控制 tau聚集,以及开发新技术来探测体外和体内的tau结构。 完成这份提案将为我提供必要的技能和培训,成为一个成功的独立 调查员

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Avi Jacob Samelson其他文献

Avi Jacob Samelson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Avi Jacob Samelson', 18)}}的其他基金

Mechanisms of tau misfolding in neurons elucidated by deep mutational scanning and CRISPR screening
通过深度突变扫描和 CRISPR 筛选阐明神经元中 tau 蛋白错误折叠的机制
  • 批准号:
    9761340
  • 财政年份:
    2019
  • 资助金额:
    $ 12.29万
  • 项目类别:

相似国自然基金

新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 批准年份:
    2010
  • 资助金额:
    26.0 万元
  • 项目类别:
    地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
  • 批准号:
    30960334
  • 批准年份:
    2009
  • 资助金额:
    22.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
  • 批准号:
    10657993
  • 财政年份:
    2023
  • 资助金额:
    $ 12.29万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10381163
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10531959
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10700991
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10518582
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10672973
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10585925
  • 财政年份:
    2022
  • 资助金额:
    $ 12.29万
  • 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
  • 批准号:
    10180000
  • 财政年份:
    2021
  • 资助金额:
    $ 12.29万
  • 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
  • 批准号:
    10049426
  • 财政年份:
    2021
  • 资助金额:
    $ 12.29万
  • 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
  • 批准号:
    10295809
  • 财政年份:
    2021
  • 资助金额:
    $ 12.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了